HOW I WOULD MANAGE A 53-YEAR-OLD WOMAN WITH NEWLY DIAGNOSED TYPE 2 DIABETES,WITH HYPERTENSION AND DYSLIPIDAEMIA

1 Stratton IM AI Adler Neil HAW on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type

2diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-12.

2 Adler AI IM Stratton Neil HAW on behalf of the UK Prospective Diabetes Study Group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412-9.

3 Garcia MJ PM McNamara Gordon T Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974; 23:105-11.

4 Turner RC H Millns Neil HAW for the UK Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: (UKPDS 23). BMJ 1998; 316:823-8.

5 Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310:356-60.

6UK Prospective Diabetes Study Group. Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years (UKPDS 13). BMJ 1995; 310:83-8.

7UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-65.

8UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53.

9 Ramsay LE B Williams Johnston GD Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13:569-92.

10 Hansson L A Zanchetti Carruthers SG for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-62.

11UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317:703-13.

12 Pyorala K TR Pedersen Kjekshus J and The Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20:614-20.

13 Goldberg RB MJ Mellies Sacks FM for the CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol And Recurrent Events (CARE) Trial. Circulation 1998; 98:2513-9.

14 Haffner SM S Lehto Ronnemaa T Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-34.

15 Wood D P Durrington Poulter N Joint British recommendations on the prevention of coronary heart disease in clinical practice. Diabetes and impaired glucose tolerance. Heart 1998; S2:S19-20.

16Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81-106.

17Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-9.